Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Active not recruiting 3Recruiting 2

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Urinary Bladder Neoplasms 8Carcinoma, Merkel Cell 6Neoplasm Metastasis 5Carcinoma, Transitional Cell 5Breast Neoplasms 5Carcinoma, Renal Cell 4Triple Negative Breast Neoplasms 2Skin Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Melanoma 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Urethral Neoplasms 1Ureteral Neoplasms 1Thymoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Primary Myelofibrosis 1Penile Squamous Cell Carcinoma (PSCC) 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Neoplasm, Residual 1Muscle Invasive Bladder Urothelial Carcinoma 1Metastatic Urothelial Cancer 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1

Interventions

Fulvestrant 63Letrozole 53Paclitaxel 49Trastuzumab 41pembrolizumab 40ribociclib 37Specimen Handling 37palbociclib 36Capecitabine 34Carboplatin 33Anastrozole 33Tamoxifen 32exemestane 29pertuzumab 28abemaciclib 28Magnetic Resonance Spectroscopy 26Cyclophosphamide 26trastuzumab deruxtecan 24Surveys and Questionnaires 21Radiotherapy 18Biopsy 18olaparib 17Standard of Care 16Docetaxel 16Blood Specimen Collection 16Taxes 14Mastectomy, Segmental 14eribulin 13elacestrant 13130-nm albumin-bound paclitaxel 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Breast Neoplasms × avelumab × 90 days × Clear all
NCT03971409 2026-04-17

InCITe

University of California, San Francisco

Phase 2 Active not recruiting
145 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03964532 2026-04-09

TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

Georgetown University

Phase 1/2 Active not recruiting
24 enrolled
Breast

Breast Neoplasms

NCT04841148 2026-04-09

PALAVY

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting
96 enrolled
Breast

Breast Neoplasms, Neoplasm, Residual

NCT04360941 2026-04-06

PAveMenT

Royal Marsden NHS Foundation Trust

Phase 1 Recruiting
45 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03573648 2026-03-19

ImmunoADAPT

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting
33 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡